Intraventricular vancomycin is an effective treatment for ventriculostomy access device infection in preterm infants. In doses ranging from 3 to 15 mg, sufficient CSF vancomycin level is generated to achieve microbiological cure without any reported adverse effects. Daily CSF drug monitoring is recommended to define dosage interval to maintain drug concentration above breakpoint of minimum inhibitory concentration.

Highlights Pharmacokinetics modelling of intraventricular vancomycin in a preterm pilot study. Intraventricular vancomycin follows a one compartment model in neonatal ventriculitis treatment. Ventricular Index, a dosing parameter, does not influence cerebrospinal fluid vancomycin levels.